Abbott Norge AS Swiftly Implements Cegedim Relationship Management’s Award Winning* Mobile Intelligence Cloud-Based CRM Solution
12.6.2012 18:00:47 CEST | Business Wire | Press release
Leading Healthcare Company Focuses on Strengthening and Maximizing Stakeholder Relationships in Norway by Leveraging Mobile Intelligence
Cegedim Relationship Management today announced that Abbott Norge AS has successfully upgraded to cloud-based Mobile Intelligence, the award-winning Pharmaceutical Customer Relationship Management (CRM) solution, for their Market Access, Epidemiology, Immunology, Medical and Specialty Care commercial teams. Abbott Norge has also implemented OneKey™, the world’s leading and most comprehensive healthcare professional (HCP) database, designed to improve targeting and segmentation. Abbott Norge AS is part of a leading global healthcare company devoted to discovering new medicines, technologies and methods to innovate healthcare.
Leveraging a Breakthrough CRM to Meet the Specific Needs of Various Commercial Teams
A primary focus of Life Sciences commercial teams is to build lasting relationships with stakeholders and inform them of their product’s advantages. To achieve this goal, commercial teams require tools that enable collaboration, visibility and efficiency. As a result, leading Life Sciences companies now demand adaptive CRM solutions that maintain regulatory requirements and provide new and effective strategies to better connect with key stakeholders.
Cegedim Relationship Management’s cloud-based Mobile Intelligence solution meets the requirements of Abbott Norge’s unique business model. The solution provides innovative, cloud-based technology, a 360° view of all customer profiles and a consistent Graphical User Interface (GUI) online and/or offline. Mobile Intelligence powered by OneKey enables the company’s commercial teams to maximize connections with integral stakeholders.
“Cegedim is able to address our core requirement of a CRM system - to facilitate the improvement of stakeholder relationships,” said Katarina Fossum, Commercial Training Manager, Abbott Norge AS. “The Mobile Intelligence and OneKey solution gives us clear visibility into our complex accounts and enables us to better target our prospects. Our teams find it very easy to use.”
The Abbott Norge deployment is part of Abbott’s global project, Mobile Intelligence MAX . In addition to Norway, Mobile Intelligence solutions have also been implemented in Germany, Spain, Sweden, Denmark, Ireland, Netherlands, Portugal and Austria; with implementations in Finland and other European countries currently in process.
“Collaborating with Abbott Norge on this ambitious initiative is an honor and further confirms the valuable functionality of Mobile Intelligence,” said Stefan Janssens, President EMEA of Cegedim Relationship Management. “As the European Life Sciences industry experiences increasingly stringent regulations that continue to transform their business models, companies are utilizing our unparalleled CRM and database solutions to improve their commercial teams’ overall effectiveness.”
* Frost & Sullivan 2011 North American Competitive Strategy Innovation Award in Mobile Sales Force Automation (SFA)
| About Cegedim Relationship Management: |
Cegedim Relationship Management is the Life Sciences industry’s leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company’s innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables more than 200,000 users in many of the world’s most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group.
To learn more, please visit: www.cegedim.com/rm
. |
||||
| About Cegedim: |
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,200 people in more than 80 countries and generated revenue of €911 million in 2011. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: www.cegedim.com . |
||||
Contact:
Cegedim Relationship Management
Global Communications
Drew
BUSTOS, +1-(908)-443-2451
drew.bustos@cegedim.com
or
Cegedim
Media
Relations
Aude BALLEYDIER, +33 (0)1 49 09 68 81
aude.balleydier@cegedim.fr
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom